Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase

[1]  P. Desgranges,et al.  Overexpression of Transforming Growth Factor-&bgr;1 Stabilizes Already-Formed Aortic Aneurysms: A First Approach to Induction of Functional Healing by Endovascular Gene Therapy , 2005, Circulation.

[2]  G. Upchurch.  Gene therapy to treat aortic aneurysms: right goal, wrong strategy. , 2005, Circulation.

[3]  Robert W. Thompson,et al.  Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. , 2005, Journal of vascular surgery.

[4]  De-Quan Li,et al.  Doxycycline inhibits TGF-beta1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells. , 2005, Investigative ophthalmology & visual science.

[5]  G. Sumara,et al.  Requirement of JNK2 for Scavenger Receptor A-Mediated Foam Cell Formation in Atherogenesis , 2004, Science.

[6]  Francesca Zazzeroni,et al.  Linking JNK signaling to NF-κB: a key to survival , 2004, Journal of Cell Science.

[7]  R. Flavell,et al.  JNK Regulates Autocrine Expression of TGF-β1 , 2004 .

[8]  É. Allaire,et al.  Vascular Smooth Muscle Cell Endovascular Therapy Stabilizes Already Developed Aneurysms in a Model of Aortic Injury Elicited by Inflammation and Proteolysis , 2004, Annals of surgery.

[9]  M. Aoki,et al.  Inhibition of Experimental Abdominal Aortic Aneurysm in the Rat by Use of Decoy Oligodeoxynucleotides Suppressing Activity of Nuclear Factor &kgr;B and ets Transcription Factors , 2003, Circulation.

[10]  R. Flavell,et al.  JNK regulates autocrine expression of TGF-beta1. , 2004, Molecular cell.

[11]  Francesca Zazzeroni,et al.  Linking JNK signaling to NF-kappaB: a key to survival. , 2004, Journal of cell science.

[12]  M. Matsuzaki,et al.  Proteasome‐dependent decrease in Akt by growth factors in vascular smooth muscle cells , 2003, FEBS letters.

[13]  A. Vercelli,et al.  A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia , 2003, Nature Medicine.

[14]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[15]  P. Libby,et al.  Elastogenesis in Human Arterial Disease: A Role for Macrophages in Disordered Elastin Synthesis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[16]  K. Kivirikko,et al.  Inactivation of the Lysyl Oxidase Gene Lox Leads to Aortic Aneurysms, Cardiovascular Dysfunction, and Perinatal Death in Mice , 2002, Circulation.

[17]  K. Nozaki,et al.  Increased Expression of Phosphorylated c-Jun Amino-terminal Kinase and Phosphorylated c-Jun in Human Cerebral Aneurysms: Role of the c-Jun Amino-terminal Kinase/c-Jun Pathway in Apoptosis of Vascular Walls , 2002, Neurosurgery.

[18]  Timothy C Greiner,et al.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. , 2002, The Journal of clinical investigation.

[19]  B. Baxter,et al.  Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. , 2002, Journal of vascular surgery.

[20]  D. Boyd,et al.  An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. , 2002, Biochimica et biophysica acta.

[21]  B. Baxter,et al.  Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. , 2002, Journal of vascular surgery.

[22]  J. Risteli,et al.  Increased amount of type III pN-collagen in AAA when compared with AOD. , 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[23]  P. Kang,et al.  Direct Activation of Mitochondrial Apoptosis Machinery by c-Jun N-terminal Kinase in Adult Cardiac Myocytes* , 2002, The Journal of Biological Chemistry.

[24]  K. Ouriel,et al.  Endovascular treatment of aortic aneurysms. , 2002, Current problems in surgery.

[25]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[26]  P. Trackman,et al.  A fluorometric assay for detection of lysyl oxidase enzyme activity in biological samples. , 2002, Analytical biochemistry.

[27]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Leinonen,et al.  Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. , 2001, Journal of vascular surgery.

[29]  J. Ferrell,et al.  Bistability in the JNK cascade , 2001, Current Biology.

[30]  A. Cho,et al.  Mitogen-Activated Protein Kinases Mediate Matrix Metalloproteinase-9 Expression in Vascular Smooth Muscle Cells , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[31]  Mark D. Huffman,et al.  Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms. , 2000, Surgery.

[32]  S. Shapiro,et al.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. , 2000, The Journal of clinical investigation.

[33]  A Daugherty,et al.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. , 2000, The Journal of clinical investigation.

[34]  D. Carey,et al.  The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. , 1999, Journal of vascular surgery.

[35]  É. Allaire,et al.  Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. , 1998, The Journal of clinical investigation.

[36]  C. Glass,et al.  Transcriptional activation of scavenger receptor expression in human smooth muscle cells requires AP-1/c-Jun and C/EBPbeta: both AP-1 binding and JNK activation are induced by phorbol esters and oxidative stress. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[37]  E. Lengyel,et al.  Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades , 1997, Oncogene.

[38]  J. Melrose,et al.  Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. , 1996, Journal of vascular surgery.

[39]  W. Parks,et al.  Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. , 1996, Journal of vascular surgery.

[40]  M. Reidy,et al.  Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. , 1994, Journal of vascular surgery.

[41]  J. Powell,et al.  Pathogenesis of abdominal aortic aneurysm , 1994, The British journal of surgery.

[42]  H. Sato,et al.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. , 1993, Oncogene.

[43]  H. Robenek,et al.  Collagen synthesis in cultured aortic smooth muscle cells. Modulation by collagen lattice culture, transforming growth factor-beta 1, and epidermal growth factor. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[44]  D. Rowe,et al.  Decreased lysyl oxidase activity in the aneurysm-prone, mottled mouse. , 1977, The Journal of biological chemistry.

[45]  J. Watson.  The key to survival. , 1963, The Journal of the American Osteopathic Association.